Hantz Financial Services Inc. Sells 2,286 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Hantz Financial Services Inc. trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 64.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,258 shares of the pharmaceutical company’s stock after selling 2,286 shares during the period. Hantz Financial Services Inc.’s holdings in Vertex Pharmaceuticals were worth $507,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $27,000. Dunhill Financial LLC boosted its position in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the last quarter. Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the third quarter worth $35,000. 90.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, December 23rd. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Scotiabank upped their price objective on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a research report on Friday. BMO Capital Markets dropped their target price on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. Finally, Truist Financial decreased their price target on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Up 5.3 %

Shares of Vertex Pharmaceuticals stock opened at $461.68 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The stock has a market cap of $118.90 billion, a price-to-earnings ratio of -232.00, a PEG ratio of 2.29 and a beta of 0.40. The firm’s 50-day moving average is $434.34 and its two-hundred day moving average is $463.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company posted $3.67 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.